4th Quarter - Termination
INTEGRATED SOLUTIONS GROUP for TEVA PHARMACEUTICALS USA
Client
Income
$60,000
Expenses
—
Terminated
Dec 31, 2013
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Monitored legislation concerning promotion of generic drug use and medicaid Drug Shortages, FDA regulations Legislation affecting settlements between generic and all brand companiesH.R. - 486 Stop Tampering with Prescription Drugs S.348 - The Prescription Drug Abuse and Prevention Act Issues concerning Rx Abuse
| Lobbyist | Covered position, as disclosed |
|---|---|
| MOSES BOYD | Counsel, Senate Commerce Committee |
| G JOHN O'HANLON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.